Drug Registration in Brazil: Decoding ANVISA’s Regulatory Pathways for Faster Market Entry

The combination of rising healthcare needs, government support, and innovation, Brazil possesses one of the largest and most rapidly expanding pharmaceutical markets in Latin America. The Agency Nacional de Vigiláncia Sanitaria (ANVISA), which was founded in 1999 and guarantees that all medications and health-related products adhere to strict standards of quality, safety, and efficacy, is at the heart of this regulatory framework. ANVISA regulates food, cosmetics, medical devices, and other health products in addition to pharmaceuticals. Brazil has made progress toward increased international regulatory convergence by actively participating in global networks like ICH and PIC/S. Smoother approval processes, quicker access to cutting-edge medications, and increased market confidence are all made possible by this alignment. However, compliance, dossier submission, product classification, and adherence to several Resolução da Diretoria Colegiada (RDCs) that specify particular pathways must all be carefully considered when navigating Brazil's regulatory environment. ANVISA has updated its procedures to strike a balance between efficiency and patient safety in response to changing regulations, such as priority/reliance reviews and digital-only submissions through Data visa. [1]

1. Overview of ANVISA Regulatory Framework

The Brazilian national regulatory body in charge of guaranteeing the quality, safety, and effectiveness of pharmaceuticals, biologicals, cosmetics, medical equipment, and food items is called the Agency Nacional de Vigiláncia Sanitaria (ANVISA).

ANVISA’s core functions include:

• Assessment and approval of novel medications and clinical studies
• Supervision of the production, importation, and marketing of regulated goods
• Facility inspections and GMP certification
• Pharmacovigilance,advertising,andlabellingregulation.
•  
• Compliance with global best practices via partnerships with PAHO, WHO, and ICH

As an experienced supplier provider of regulatory affairs services in Brazil, DDReg works closely with local officials and ANVISA to provide timely, accurate, and compliant regulatory submissions. In order to keep you informed about ANVISA regulations, we also offer regulatory intelligence. [2]

Organizations part of Authorisation procedure in Brazil

In Brazil, CONEP (Central), CEP (Local Committee), and ANVISA are the three different organizations responsible for reviewing and approving regulatory documentation to begin a clinical study. The ANVISA and CONEP procedures operate concurrently. The Central Ethics Committee, known as the National Committee of Ethics in Research (CONEP), is connected to the Ministry of Health and is responsible for examining and approving the ethical aspects of clinical trials in Brazil. [3]

2. Drug Registration Categories and Regulation in Brazil

New Drug

Before being registered with ANVISA, these innovative pharmaceutical products' safety, effectiveness, and quality are proven through both non-clinical and clinical research. Innovator medicinal formulations may contain a novel molecular entity, a novel or modified structure, a new indication, a new dosage form, a new dose administration technique, a new combination, or a new therapeutic role. Generic and comparable medications are compared to innovator medications. The requirements for innovator drug marketing authorization are listed in:

• Law No. 6,360/1976 governs the registration of pharmaceutical products, medications, and drugs. Most of the rules governing pharmaceutical productsinBrazilarefoundinthislaw.
•  
• In Brazil, the marketing clearance of new drugs is governed by Resolution No. 136/2003.

The "product be recognised as safe and effective" and the submission of thorough data are two requirements that must be fulfilled in order for a novel drug to be registered (Article 16, Law No. 6,360/1976). A technical report and reports from pre-clinical and clinical trials must be submitted in compliance with the particular guidelines specified in Resolution No. 136/2003 in order to obtain marketing clearance. In contrast, Brazilian regulators continue to grant marketing approvals for innovative medications to local businesses that have not yet conducted a clinical trial. [2]

Generic Drug

A medication that shares the same active ingredient, dosage form, administration method, strength, and therapeutic use as the innovator drug and is bioequivalent to the reference drug. These can be used interchangeably with innovator drugs and are only made after the patent and exclusivity rights have expired. The CBD (Common Brazilian Denomination) or, in the event that this is not possible, the CID (Common International Denomination) must certify the safety, efficacy, and quality of these drugs. Brazil’s Generic Drug Act, approved by the Ministry of Health in 1999 under Law No. 9.787/1999, may be sold if it is manufactured in accordance with ANVISA quality standards and is pharmaceutically equivalent to the reference product. The cost of generic medications is typically 65% lower than that of patent or innovator medications. [4]

Similar medicines

The active ingredients, dosage form, strength, indication, and dosage of these branded generics are allegedly identical to those of innovator medications. Before generic versions were introduced in 1999, these medications had been around for a very long time. Resolution No. 1/1994 contains the marketing approval requirements for these products. Resolution RDC No. 133 of May 29, 2003 established pharmacokinetic and pharmacological equivalency studies as requirements for the authorization of comparable products.

This resolution also made it possible to compare similar medications with distinct pharmacokinetic characteristics, like area under the curve (AUC) and Cmax, to their reference product. In these situations, the product must be registered with a modified dose or dosage requirements; further efficacy and safety studies are not necessary. According to RDC No. 134/2003, In these situations, the product must be registered with a modified dose or dosage requirements, but further efficacy and safety studies are not necessary. [5] According to RDC No. 134/2003, similar medications that have already been approved must follow the guidelines of Resolution No. 133/2003; if not, they must submit clinical studies to change their registration to innovator medications.

Resolution No. 17/2007 repealed Resolution No. 133/2003 and required comparable drugs to be subjected to the same in vitro study requirements as generic drugs, including statistical analysis. However, Resolution No. 17/2007 does not specify that these drugs must be bioequivalent to their reference products or that similar drugs cannot be substituted for their reference drugs. In 2014, RDC No. 60/2014 was published for the registration of drugs (Innovator, generic, and similar drugs) in Brazil.

Since then, all similar medications have shown therapeutic equivalency, enabling them to replace reference drugs. Resolution RDC 200/2017 is the current Brazilian regulation for the marketing authorization of pharmaceuticals (including innovator, generic, and similar drugs). [6]

3. Drug Registration process in Brazil

Fig 1. Steps of Drug Registration in Brazil [5]

Compliance with ANVISA standards helps ensure that your product meets Brazilian health and safety regulations, supporting market entry and building consumer trust. 

• Authorization Requirements: When handling controlled substances like narcotics or psychotropics, pharmaceutical companies operating in Brazil are required to obtain an authorized license, Autorção Especial de Empresa (AE), from ANVISA. RDC No. 16/2014 governs the handling, production, and processing of materials for such products.
• Petition and Protocol Registration: The secret to the registration process is creating a comprehensive petition and registering a protocol with ANVISA. Use the proper Código de Assunto (subject code) to accurately classify the product in order to expedite ANVISA's review process.
• Product Classification: Accurately classifying your product is essential. Products that require special registration procedures include agrotóxicos, health products, and medical devices.
• Medical Devices Registration (RDC 185/2001): Syringes, needles, and other medical supplies go through a different ANVISA registration process. RDC 185/2001 governs them, and unlike pharmaceuticals, they need risk-based classification and compliance checks. 
• Continuous Compliance and Renewals: Product registrations in Brazil are good for ten years, after which they need to be renewed. This process should begin six to twelve months before expiration to avoid disruptions. [7]

4. Classification of Drug Product in ANVISA

ANVISA oversees several drug classes each with unique regulatory pathways based on relevant RDCs.  

Table1. Classification of Drug Product In ANVISA [8]

5. Structure of Registration Dossier

The registration dossier in Brazil follows a two-part structure and is prepared in the electronic Common Technical Document (eCTD) format. Part 1, corresponding to Module 1, comprises administrative data and local knowledge. Part 2, encompassing Modules 2, 3, 4, and 5, contains summaries of preclinical investigations, chemistry, manufacturing, and controls (CMC) information, nonclinical data and reports, and clinical data and Reports. [9]

6. Dossier requirements for drug registration in Brazil

Table 2. Dossier Requirement for drug registration in Brazil [9]

7. CTD modules that comply with ICH guidelines

Dossier submissions must adhere to the Common Technical Document (CTD) format, which is in line with ICH guidelines

Module 1: Administrative Information and Prescribing Information

This module should contain documents specific to each region; for example, application forms or the proposed label for use in the region. The content and format of this module can be specified by the relevant regulatory authorities.

Module 2. Common Technical Document Summaries

 Module 2 should begin with a general introduction to the pharmaceutical, including its pharmacologic class, mode of action, and proposed clinical use. In general, the Introduction should not exceed one page.

 Module 2 should contain 7 sections in the following order:

• CTD Table of Contents

• CTD Introduction

• Quality Overall Summary

• Nonclinical Overview

• Clinical Overview

• Nonclinical Written and Tabulated Summaries

• Clinical Summary

Module 3:  Manufacturing and quality (CMC data)

Information on Quality should be presented in the structured format described in Guideline M4Q.

Module 4: Nonclinical Study reports(pharmacology/toxicology).

The nonclinical study reports should be presented in the order described in                        Guideline M4S.

Module 5: Clinical Study reports (Trials, BE, Comparability)

The human study reports and related information should be presented in the order described in Guideline M4E.

Submissions must include the Certificate of Pharmaceutical Product (CPP) GMP certificate, Portuguese labelling and be filed electronically through the Data visa system.  

International applicants are required to designate a legally registered partner in Brazil to serve as the accountable party for importation distribution marketing authorization and post-market surveillance. [10]

8. Anvisa Review Process of Registration Dossier

Fig 2. Anvisa Review Process of Registration Dossier [5]

9. ANVISA GMP Inspection

The content included in the application for GMP inspection:

• A filled-out, signed, and stamped petition form.
• A current GMP certificate from the country of origin's health authorities. There is no need for a sworn translation for certificates in either Spanish or English.
• There are two different kinds of master files: Site Master File (SMF) and Plant Master File (AMP).
• The Periodical Product Review (RPP) and, if available, an Inspection Report from additional health authorities in the country of origin.
• The following procedures are part of ANVISA's inspection schedule:
• Approximately 6 months after receiving the inspection request, ANVISA conducts an inspection of the production facility.
• Following the inspection, ANVISA grants the company the Good Manufacturing Practices certificate within a period of 45 to 60 days. [11]

 Timelines for ANVISA inspection:

ANVISA inspection of manufacturing site occurs approximately 6 months after submitting the request for inspection to ANVISA

ANVISA issues the Good Manufacturing Practice certificate to company 45 to 60 days after inspection [9]

10.  Regulatory Pathways for Faster Market Entry in Brazil

To speed up drug registration and market access ANVISA provides several mechanisms as mentioned below:

1. Standard Market Authorization

• Timeline: 365 days (standard), 120 days (priority review).
• Notes: Official decision-making may extend these periods by up to one third. 

2. Priority (Fast-Track) Review – RDC 205/2017

• The manufacturer satisfies ANVISA within 60 days of submission to another authority (such as the FDA or EMA).

• ANVISA has sixty days to make a decision or ask for more information following a formal request made within thirty days.

3. Reliance and Expedited Pathway – RDC 913/2024, IN 289/2024

• Conditional approvals or quality modifications that require approval from stringent authorities (FDA, EMA, Health Canada, PMDA) are accepted by ANVISA.

• Simplifies biologics authorization and tech-transfer submissions.

4. Simplified Pathways for Biosimilars and Biologics – RDC 875/2024

• Some clinical and non-clinical studies may be skipped if solid comparability data is available. [12]

11. Recent Regulatory Updates for Drug Registration in Brazil

The Recent Changes that are to be followed for faster market approval are stated below: 

• New and Innovative Medicines (2022): ANVISA unveiled an updated framework in October 2022 that provides both comprehensive and shortened registration pathways. When feasible, it allows data from previous clinical trials to be substituted for new ones, fostering innovation without compromising safety.
• Resolution 954: comes into effect on January 21, 2025, and guarantees uniformity in quality and pricing compliance by streamlining the registration process and restricting submissions to businesses in the same economic group. [13]
• API GMP certification or CADIFA: Available to foreign API manufacturers. It is transferred to other product registrations after confirming GMP compliance. Approval periods usually last for 15–18 months or up to 24 months for fixed-dose combinations.

• Completely paperless filing: ANVISA will completely phase out paper submissions starting on March 13, 2025, and only accept digital dossiers via Data visa/eCTD. [14]

12. Challenges associated with Drug Registration in Brazil

• Delays in GMP Inspections: Product approvals are frequently delayed by backlogs caused by resource limitations.
• Complex Dossier Requirements: Dossiers that are globally compliant might still need to be modified for ANVISA.
• Language Barriers: Portuguese translations are more complicated and prone to mistakes.
• Pharmacovigilance Oversight: Strong, regionally tailored pharmacovigilance systems are needed in Brazil. [15]

Longer market entry timelines are caused by the burden of comprehensive data submissions for clinical trials and manufacturing procedures as well as possible language barriers and regulatory changes. [16]